Merck Matches Sandoz With Canadian Etanercept Indications
Brenzys Biosimilar To Enbrel Gets Further Indications Already Enjoyed By Erelzi
Merck, Sharp & Dohme’s Brenzys biosimilar version of Amgen’s Enbrel has received four new indications in Canada, bringing it in line with Sandoz’ rival biosimilar, Erelzi.
